PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

Pharmapack Europe unpacks key drivers and challenges in 2020

Digital Value-Added Medicines, waste management and the use of blockchain identified as key trends for the upcoming year Paris, 28 January 2020: Pharmapack ...
Continue Reading →
News

Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%

Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching b...
Continue Reading →
News

Epizyme scores FDA nod for rare cancer med Tazverik but prices it for a future indication: analyst

On the heels of a unanimous FDA panel vote last month in favor of its application, Epizyme’s rare cancer med Tazverik scored U.S. approval Thursd...
Continue Reading →
News

Roche’s Tecentriq flops in postsurgery muscle-invasive bladder cancer

Bladder cancer may have been the first FDA-approved indication for Tecentriq—as the first PD-1/L1 inhibitor to enter the area—but that doesn’t mean the Roche drug ca...
Continue Reading →
News

New sickle cell drugs from Novartis, GBT need big discounts: ICER draft

When Global Blood Therapeutics won approval for its new sickle cell disease drug Oxbryta last year, execs predicted a “paradigm shift” in the way pati...
Continue Reading →
News

Krystal Biotech investing up to $90M on facility for its gene therapies

Krystal Biotech is confident enough about its pipeline of candidates of gene therapies for treating skin diseases that has started work on a new commercial manufactu...
Continue Reading →
News

China repurposes AbbVie HIV drug as Big Pharma rallies to combat deadly coronavirus

To battle the coronavirus emergency, Chinese government and medical experts are taking some unconventional measures, including publicly backing off-label use of a Bi...
Continue Reading →
News

Merck KGaA antes up €250M to bridge R&D with manufacturing

Merck KGaA has big plans for a site in Switzerland where it intends to knit together biologics development and manufacturing.  The German drugmaker today said...
Continue Reading →
News

Biologics and DTC: Mainstream ad campaigns now price of admission for biologic brands

Speciality biologic drugs may be a smaller share of the market, but they're growing fastest—and competition is fierce. No surprise, then, that more and more biologic...
Continue Reading →
News

J&J’s ketamine depression drug Spravato spurned by England’s influential cost watchdogs

For Johnson & Johnson’s depression nasal spray Spravato, pricing has not only attracted criticism in the U.S. but also hurt its effort to win backing from Englan...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026